Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Obseva SA OBSEF

Healthcare Biotechnology

Obseva SA is a Switzerland-based company active in the pharmaceutical and medical research sector. The Company develops oral compounds to treat women’s reproductive health conditions from conception to birth. Its pipeline includes three product candidates: Linzagolix (OBE2109), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist intended for the treatment of endometriosis and... see more

Add To Watchlist

Recent & Breaking News (GREY:OBSEF)

ObsEva SA to present at the H.C Wainwright 22nd Annual Global Investment Virtual Conference, September 14-16, 2020

GlobeNewswire September 8, 2020

ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement Priced At-The-Market of Common Shares and 15-Month Purchase Warrants for Potential Additional Gross Proceeds of $23.9 Million

GlobeNewswire September 3, 2020

ObsEva SA to present at the Wedbush PacGrow Healthcare Virtual Conference, August 11 - 12, 2020

GlobeNewswire August 7, 2020

ObsEva Announces Second Quarter 2020 Financial Results and Business Update

GlobeNewswire August 6, 2020

ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020

GlobeNewswire July 15, 2020

ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids

GlobeNewswire July 6, 2020

ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020

GlobeNewswire July 3, 2020

ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA

GlobeNewswire July 1, 2020

ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids

GlobeNewswire June 29, 2020

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020

GlobeNewswire June 9, 2020

ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis

GlobeNewswire June 4, 2020

ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020

GlobeNewswire May 29, 2020

ObsEva Annual General Meeting 2020

GlobeNewswire May 8, 2020

ObsEva Announces First Quarter 2020 Financial Results and Business Update

GlobeNewswire May 5, 2020

ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis

GlobeNewswire April 22, 2020

ObsEva to Increase Issued Share Capital by Creating Additional Treasury Shares

GlobeNewswire April 14, 2020

ObsEva SA Announces New Interim Chief Financial Officer

GlobeNewswire April 6, 2020

ObsEva SA: New Date Announcement for AGM

GlobeNewswire March 27, 2020

ObsEva Provides Update Related to COVID-19 Pandemic

GlobeNewswire March 23, 2020

ObsEva SA Link to Annual Report 2019

GlobeNewswire March 5, 2020